Skip to main content

Cerus Value Stock - Dividend - Research Selection

Cerus

ISIN: US1570851014 , WKN: 905249

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company\'s INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Tracking Baker Brothers Portfolio - Q3 2025 Update

2025-12-16
Discover Baker Brothers' Q3 2025 portfolio shifts—see top biotech stock picks, strategic increases, and key holdings.

Cerus: IFC Growth And RBC Optionality

2025-11-23
Discover why CERS is a strong buy as it innovates blood transfusion safety with Intercept technology and eyes near-term positive cash flow.

3 Promising Penny Stocks With Market Caps Under $400M

2025-11-10
As the U.S. stock market grapples with recent volatility, highlighted by the Nasdaq's worst week since 'Liberation Day,' investors are increasingly seeking opportunities beyond traditional large-cap stocks. Penny stocks, despite their somewhat outdated moniker, still hold relevance as they often represent smaller or newer companies that can offer significant growth potential at lower price points. By focusing on those with strong financials and clear growth prospects, investors may uncover...

Cerus Corp (CERS) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Shifts Amid ...

2025-11-07
Cerus Corp (CERS) reports a 15% revenue increase and strategic transitions, despite facing margin pressures and regulatory delays.

Cerus: Q3 Earnings Snapshot

2025-11-06
CERS) on Thursday reported a loss of $19,000 in its third quarter. On a per-share basis, the Concord, California-based company said it had a loss of less than 1 cent. The biomedical products company posted revenue of $52.7 million in the period.

Cerus Corporation Announces Record Results for Third Quarter 2025 and Raises Full Year 2025 Product Revenue Guidance

2025-11-06
CONCORD, Calif., November 06, 2025--Cerus Corporation (Nasdaq: CERS) announced today financial results for the third quarter ended September 30, 2025, and provided a business update.

Cerus Corporation (CERS) Q3 2025 Earnings Call Transcript

2025-11-06
Cerus Corporation (CERS) Q3 2025 Earnings Call November 6, 2025 4:30 PM ESTCompany ParticipantsTimothy LeeWilliam Greenman - President, CEO &...

Cerus Corporation Announces Abstracts and Industry Workshop on IFC at the 2025 AABB Annual Meeting

2025-10-21
CONCORD, Calif., October 21, 2025--Cerus Corporation (Nasdaq: CERS) announced today that it will host an industry workshop on the benefits of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, commonly referred to as INTERCEPT Fibrinogen Complex, or IFC, at the 2025 Association for the Advancement of Blood and Biotherapies (AABB) Annual Meeting, taking place in San Diego, California from October 25 through October 28. The AABB Annual Meeting attracts healthcare professionals, scientists, and

Undervalued Small Caps With Insider Action To Watch In October 2025

2025-10-21
As the U.S. stock market experiences a robust start to the week, with major indices like the S&P 500 and Nasdaq posting significant gains, investors are keenly observing how ongoing economic factors such as trade developments and government shutdowns impact smaller companies. In this dynamic environment, small-cap stocks with insider activity can offer intriguing opportunities due to their potential for growth and resilience amidst broader market fluctuations.

Cerus Corporation to Release Third Quarter 2025 Financial Results on November 6, 2025

2025-10-16
CONCORD, Calif., October 16, 2025--Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2025 financial results will be released on Thursday, November 6, 2025, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company’s financial results and provide a general business overview and outlook.